News

Twist Bioscience Unveils Innovative FlexPrep Ultra-High Throughput Kit

Twist Bioscience Unveils Innovative FlexPrep Ultra-High Throughput Kit

Revolutionizing Genomic Workflows with Twist Bioscience's FlexPrep Kit

Twist Bioscience Corporation (NASDAQ: TWST) has made a significant contribution to the field of genomics by introducing the FlexPrep Ultra-High Throughput Library Preparation Kit. This innovative product is specifically designed to cater to the growing demands in agrigenomics and population genomics. Its launch is set to streamline processes and boost efficiency for researchers delving into these critical applications.

Understanding FlexPrep Technology

The FlexPrep kit is equipped with a proprietary Twist-developed enzyme, allowing for high throughput at a lower cost. This is particularly crucial in applications requiring the analysis of tens of thousands to millions of samples simultaneously, a need that arises when researchers seek to go beyond single nucleotide polymorphisms (SNPs). With the introduction of Normalization by Ligation™ (NBL) technology, the FlexPrep kit simplifies the library preparation process, removing the necessity for prior sample quantitation.

Simplifying Sample Preparation

One of the main benefits of the FlexPrep kit is its ability to self-normalize samples, which can often consume valuable time and resources in laboratory settings. Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, emphasizes that this novel approach enables researchers to handle large-scale projects more effectively, enhancing throughput while reducing costs. With the FlexPrep UHT kit, scientists can manage up to 1,152 samples in a single 96-well plate run, significantly cutting down on time and resource expenditure compared to traditional methods.

Efficiency and Cost Reduction

The FlexPrep technology not only boosts workflow efficiency but also notably decreases the amount of consumables required. For instance, researchers using the FlexPrep UHT kit can reduce their need for pipette tips from over 17,000 in a standard kit to under 4,000, yielding substantial savings. Furthermore, the kit incorporates advanced tagging methods, employing Twist's 3,000 unique dual indexes (UDIs). This feature ensures that studies are not limited by multiplexing capacity, leading to enhanced genomic analysis capabilities.

Collaboration for Enhanced Genomic Solutions

In an effort to further enrich their service offerings, Twist Bioscience is collaborating with Gencove, a frontrunner in low-pass genome sequencing and analysis software. This partnership aims to provide comprehensive analysis solutions for researchers employing the FlexPrep kit, ultimately aiding them in gaining insights from their genomic data efficiently and affordably.

Competitive Edge in Genomics

Twist Bioscience's commitment to advancing genomic research is reflected in its rigorous development of cutting-edge tools for next-generation sequencing (NGS). The FlexPrep UHT kit is a testament to this mission, enabling researchers to transition from conventional microarray technologies to superior NGS methodologies. As more labs adopt advanced genomic practices, this innovative kit positions its users at the forefront of genomics.

Real-world Impact

Angela Jones, NGS operations manager at Vanderbilt University Medical Center, shared her experiences, stating, "The normalization adapters enable us to skip costly quantification steps, and the sample barcodes reduce the number of PCR reactions and cleanings significantly. This efficiency not only increases throughput but also saves time and money.” Such testimonials highlight the practical advantages that the FlexPrep UHT kit brings to life in research environments.

About Twist Bioscience

Twist Bioscience stands as a leading name in synthetic biology and genomics. Renowned for its groundbreaking DNA synthesis platform, Twist advocates for the industrialization of biology engineering. Their proprietary technology, which manufactures synthetic DNA on silicon chips, sets them apart in the industry. Offering a variety of products spanning synthetic genes to tools designed for NGS preparation, Twist continually seeks new opportunities in fields such as agricultural genomics, drug discovery, and even digital data storage.

Frequently Asked Questions

What is the FlexPrep Ultra-High Throughput Library Preparation Kit?

The FlexPrep kit by Twist Bioscience is designed to simplify and accelerate the preparation of genomic libraries, specifically for agrigenomics and population genomics applications.

How does NBL technology work?

Normalization by Ligation™ (NBL) technology self-normalizes samples, eliminating the need for complex pre-preparation quantification, thus streamlining workflows and reducing processing time.

What benefits does FlexPrep provide in terms of cost?

Using the FlexPrep kit can reduce consumables and reagents, lowering overall costs significantly compared to traditional methods, making genomic research more affordable.

Who is Twist Bioscience collaborating with?

Twist Bioscience is collaborating with Gencove to offer integrated genomic analysis solutions that complement the FlexPrep kit, enabling researchers to analyze their data more effectively.

Why is the FlexPrep Kit advantageous for researchers?

It allows researchers to process a larger number of samples more efficiently, reducing the time spent on preparation and processing while enhancing data quality and throughput.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

WeFetch AI: A New Era in Barcode Precision

Updated Category News Views 201

WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...

Continue Reading
Gaine Expands Healthcare Data Solutions Ahead of HLTH 2026

Updated Category News Views 227

Ever felt like healthcare systems are still stuck in a bygone era, struggling with data flinging through the void? Well, Gaine Technology is throwing down its gauntlet to change that narrative. Successful in pharmaceuticals and life sciences, they're turbocharging their Consent and Preference Management solution across the vast, tangled web of healthcare markets just in...

Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early

Updated Category News Views 183

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 158

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 153

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
Samuel Oschin Center Opens, Promising Wonder

Updated Category News Views 198

A Grand New Space for Space Well, here's a sight for sore eyes—California Science Center's Samuel Oschin Air and Space Center just swung its doors open wide, and boy, it's a beast of a place. Housing a spectacle like the Space Shuttle Endeavour in a vertical launch position, it's as if they've reached up and snagged a piece of the sky itself for their exhibits. They're...

Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 223

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 206

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Updated Category News Views 211

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 244

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading

Top 5 Most Recently Viewed Articles

CJ BIO's Bold Steps for Sustainable Animal Nutrition

Updated Category News Views 558

Breaking New Ground in Animal Nutrition Picture this: industry big wigs and farmers alike, all rubbing elbows at EuroTier 2026, the grand meeting ground for animal nutrition's future. This is where CJ BIO is flexing its muscles, not by just tossing ingredients into the mix, but by revolutionizing them under the banner "Feed Intelligence for Sustainable Performance." Now,...

Continue Reading
ParaZero Technologies Achieves Nasdaq Compliance Milestone

Updated Category News Views 130

ParaZero Technologies Regains Compliance with Nasdaq Standards Recent developments in the aerospace sector have highlighted the impressive strides made by ParaZero Technologies Ltd. (Nasdaq: PRZO), an innovator in safety systems for drones and urban air mobility vehicles. The company has reached a significant milestone, regaining compliance with Nasdaq’s minimum bid...

Continue Reading
Revolutionizing Semiconductor Design with AI Integration

Updated Category News Views 389

Ricursive Intelligence Launches Groundbreaking AI Lab Ricursive Intelligence is setting a new standard in semiconductor design with the introduction of its innovative AI lab. This initiative aims to seamlessly blend artificial intelligence with chip creation to expedite progress within the tech landscape. Major Funding and Valuation Boost The company recently raised an...

Continue Reading
Craneware plc Publishes a Key Trading Disclosure Notice

Updated Category News Views 219

Introduction to Craneware plc's Trading Disclosure Craneware plc, a prominent player in the healthcare technology space, has officially announced a significant trading disclosure following the rules established in the Takeover Code. This notification serves as an important communication to stakeholders about recent trading activities that involve exempt principal traders...

Continue Reading
Stocks to Consider Amidst Global Market Uncertainty

Updated Category News Views 150

The Current Market Landscape As geopolitical tensions rise, markets are experiencing undercurrents of uncertainty. Recent tariff threats have sent ripples through global financial markets, particularly affecting investor confidence in stocks. The atmosphere is becoming increasingly cautious, with many investors wondering which stocks might shield their portfolios during...

Continue Reading